4.1 Article

Schwannomatosis associated with multiple meningiomas due to a familial SMARCB1 mutation

期刊

NEUROGENETICS
卷 11, 期 1, 页码 73-80

出版社

SPRINGER
DOI: 10.1007/s10048-009-0204-2

关键词

Schwannomatosis; Multiple meningiomas; SMARCB1 mutation

向作者/读者索取更多资源

Schwannomatosis (MIM 162091) is a condition predisposing to the development of central and peripheral schwannomas; most cases are sporadic without a clear family history but a few families with a clear autosomal dominant pattern of transmission have been described. Germline mutations in SMARCB1 are associated with schwannomatosis. We report a family with multiple schwannomas and meningiomas. A SMARCB1 germline mutation in exon 1 was identified. The mutation, c.92A > T (p.Glu31Val), occurs in a highly conserved amino acid in the SMARCB1 protein. In addition, in silico analysis demonstrated that the mutation disrupts the donor consensus sequence of exon 1. RNA studies verified the absence of mRNA transcribed by the mutant allele. This is the first report of a SMARCB1 germline mutation in a family with schwannomatosis characterized by the development of multiple meningiomas.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.1
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Clinical Neurology

Epigenomic, genomic, and transcriptomic landscape of schwannomatosis

Sheila Mansouri, Suganth Suppiah, Yasin Mamatjan, Irene Paganini, Jeffrey C. Liu, Shirin Karimi, Vikas Patil, Farshad Nassiri, Olivia Singh, Yogi Sundaravadanam, Prisni Rath, Roberta Sestini, Francesca Gensini, Sameer Agnihotri, Jaishri Blakeley, Kimberly Ostrow, David Largaespada, Scott R. Plotkin, Anat Stemmer-Rachamimov, Marcela Maria Ferrer, Trevor J. Pugh, Kenneth D. Aldape, Laura Papi, Gelareh Zadeh

Summary: Schwannomatosis is a genetic cancer predisposition syndrome characterized by multiple neuronal tumors called schwannomas. Genomic analysis revealed distinct features in SWNTS-SWNs compared to non-syndromic sporadic SWNs, including four DNA methylation subgroups and novel genetic alterations. Specific transcriptional programs associated with painful SWNTS-SWNs were identified, which may be utilized for syndrome management.

ACTA NEUROPATHOLOGICA (2021)

Correction Biochemistry & Molecular Biology

ESHG warns against misuses of genetic tests and biobanks for discrimination purposes (Jan, 10.1038/s41431-020-00786-6, 2021)

Francesca Forzano, Maurizio Genuardi, Yves Moreau

EUROPEAN JOURNAL OF HUMAN GENETICS (2021)

Article Multidisciplinary Sciences

Pool testing on random and natural clusters of individuals: Optimisation of SARS-CoV-2 surveillance in the presence of low viral load samples

Michela Baccini, Emilia Rocco, Irene Paganini, Alessandra Mattei, Cristina Sani, Giulia Vannucci, Simonetta Bisanzi, Elena Burroni, Marco Peluso, Armelle Munnia, Filippo Cellai, Giampaolo Pompeo, Laura Micio, Jessica Viti, Fabrizia Mealli, Francesca Maria Carozzi

Summary: In the context of low infection prevalence, pool testing is useful in saving resources and improving surveillance efficiency. By selecting appropriate group sizes and exploiting natural clustering structures, such as families or school classes, pool testing can be optimized to increase the probability of identifying positive samples, even with low viral loads, in the same pool.

PLOS ONE (2021)

Article Genetics & Heredity

Prevalence of bladder cancer in Costello syndrome: New insights to drive clinical decision-making

Chiara Leoni, Filomena Valentina Paradiso, Nazario Foschi, Marta Tedesco, Francesco Pierconti, Sara Silvaroli, Mario Di Diego, Lisa Birritella, Francesca Pantaleoni, Claudia Rendeli, Roberta Onesimo, Germana Viscogliosi, Pierfrancesco Bassi, Lorenzo Nanni, Maurizio Genuardi, Marco Tartaglia, Giuseppe Zampino

Summary: Costello syndrome patients have a high prevalence of bladder lesions, including premalignant lesions and epithelial dysplasia. Personalized screening protocols are crucial for managing these patients.

CLINICAL GENETICS (2022)

Review Oncology

The challenge of the Molecular Tumor Board empowerment in clinical oncology practice: A Position Paper on behalf of the AIOM- SIAPEC/ IAP-SIBioC-SIC-SIF-SIGU-SIRM Italian Scientific Societies

Antonio Russo, Lorena Incorvaia, Ettore Capoluongo, Pierosandro Tagliaferri, Antonio Galvano, Marzia Del Re, Umberto Malapelle, Rita Chiari, Pierfranco Conte, Romano Danesi, Matteo Fassan, Roberto Ferrara, Maurizio Genuardi, Paola Ghiorzo, Stefania Gori, Fiorella Guadagni, Antonio Marchetti, Paolo Marchetti, Massimo Midiri, Nicola Normanno, Francesco Passiglia, Carmine Pinto, Nicola Silvestris, Giovanni Tallini, Simona Vatrano, Bruno Vincenzi, Saverio Cinieri, Giordano Beretta

Summary: The development of innovative technologies and advances in genetics and genomics have provided new opportunities for personalized treatment in oncology. However, this approach is challenging and requires collaboration among different specialists to ensure access and economic sustainability of required genomic tests. This position paper by Italian scientific societies critically discusses the technologies, criteria for patient selection, sample selection and analysis, and regulatory and pharmaco-economic issues.

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2022)

Editorial Material Biochemistry & Molecular Biology

The use of polygenic risk scores in pre-implantation genetic testing: an unproven, unethical practice

Francesca Forzano, Olga Antonova, Angus Clarke, Guido de Wert, Sabine Hentze, Yalda Jamshidi, Yves Moreau, Markus Perola, Inga Prokopenko, Andrew Read, Alexandre Reymond, Vigdis Stefansdottir, Carla van El, Maurizio Genuardi

Summary: Although polygenic risk score analyses on embryos (PGT-P) are being marketed to parents using in vitro fertilisation as a tool for selecting embryos with lower disease risk, the utility of PRS in this context is limited and lacks clinical research support. Patients need to be informed about the limitations of using PRSs in this way, and a societal debate about the selection of individual traits should take place before further implementation of this technique in this population.

EUROPEAN JOURNAL OF HUMAN GENETICS (2022)

Article Genetics & Heredity

Variants of uncertain significance (VUS) in cancer predisposing genes: What are we learning from multigene panels?

Emanuela Lucci-Cordisco, Simona Amenta, Arianna Panfili, Jesus del Valle, Gabriel Capella, Marta Pineda, Maurizio Genuardi

Summary: The number of VUS identified in cancer predisposing genes has not decreased over time due to widespread multigene panel testing. Recent studies show a higher relative yield of VUS compared to pathogenic variants, and it is important to promote the wider use of gene specific interpretation criteria for variant classification optimization.

EUROPEAN JOURNAL OF MEDICAL GENETICS (2022)

Article Genetics & Heredity

Co-Occurrence of Fragile X Syndrome with a Second Genetic Condition: Three Independent Cases of Double Diagnosis

Elisabetta Tabolacci, Maria Grazia Pomponi, Laura Remondini, Roberta Pietrobono, Daniela Orteschi, Veronica Nobile, Cecilia Pucci, Elisa Musto, Marika Pane, Eugenio M. Mercuri, Giovanni Neri, Maurizio Genuardi, Pietro Chiurazzi, Marcella Zollino

Summary: Fragile X syndrome (FXS) is the most common form of inherited intellectual disability and autism caused by a gene mutation, and can sometimes coexist with other genetic disorders such as Duchenne muscular dystrophy (DMD), PPP2R5D--related neurodevelopmental disorder, and 2p25.3 deletion. These rare cases demonstrate the complex relationship between FXS and other genetic conditions, with the potential for modifying clinical features in patients.
Article Oncology

European experts consensus: BRCA/homologous recombination deficiency testing in first-line ovarian cancer

I Vergote, A. Gonzalez-Martin, I Ray-Coquard, P. Harter, N. Colombo, P. Pujol, D. Lorusso, M. R. Mirza, B. Brasiuniene, R. Madry, J. D. Brenton, M. G. E. M. Ausems, R. Buettner, D. Lambrechts

Summary: This study aimed to establish a European-wide consensus on genetic testing and clinical management for patients with newly diagnosed advanced ovarian cancer, as well as biomarkers for predicting the effectiveness of PARPi in first-line treatment. The consensus recommendations, based on input from experts across Europe, provide clear guidance on BRCA and HRR deficiency testing for these patients.

ANNALS OF ONCOLOGY (2022)

Article Gastroenterology & Hepatology

Gastrointestinal manifestations in PTEN hamartoma tumor syndrome

Giuseppe D'Ermo, Maurizio Genuardi

Summary: PTEN hamartoma tumor syndrome (PHTS) is a heterogeneous set of multisystem disorders caused by germline pathogenic variants in the PTEN tumor suppressor gene. It is characterized by developmental anomalies and proliferative lesions. Patients often present with gastrointestinal polyps and an increased risk of colorectal cancer, requiring colonoscopy surveillance from the age of 35-40. There may also be other symptoms such as eosinophilic gastrointestinal disorders, but their association with PHTS is still uncertain.

BEST PRACTICE & RESEARCH CLINICAL GASTROENTEROLOGY (2022)

Article Genetics & Heredity

Pediatric High Grade Glioma Classification Criteria and Molecular Features of a Case Series

Anna Maria Buccoliero, Laura Giunti, Selene Moscardi, Francesca Castiglione, Aldesia Provenzano, Iacopo Sardi, Mirko Scagnet, Lorenzo Genitori, Chiara Caporalini

Summary: Pediatric high-grade gliomas (pHGGs) are a heterogeneous group of tumors, with three main molecular types and several subtypes. In our study of 11 non-related pHGG samples, TP53 and H3F3A were found to be the most commonly mutated genes.
Article Immunology

A Protective HLA Extended Haplotype Outweighs the Major COVID-19 Risk Factor Inherited From Neanderthals in the Sardinian Population

Stefano Mocci, Roberto Littera, Stefania Tranquilli, Aldesia Provenzano, Alessia Mascia, Federica Cannas, Sara Lai, Erika Giuressi, Luchino Chessa, Goffredo Angioni, Marcello Campagna, Davide Firinu, Maria Del Zompo, Giorgio La Nasa, Andrea Perra, Sabrina Giglio

Summary: The study found that Sardinian patients carrying the high-risk variant (rs35044562) of the Neanderthal risk locus have an increased risk of developing severe symptoms. However, in the Sardinian population, the extended haplotype of HLA-A*02:01, B*18:01, DRB*03:01 has a protective effect and can counteract the high risk associated with the Neanderthal locus.

FRONTIERS IN IMMUNOLOGY (2022)

Article Pharmacology & Pharmacy

STOP Pain Project-Opioid Response in Pediatric Cancer Patients and Gene Polymorphisms of Cytokine Pathways

Giada Crescioli, Niccolo Lombardi, Laura Vagnoli, Alessandra Bettiol, Laura Giunti, Valentina Cetica, Maria Luisa Coniglio, Aldesia Provenzano, Sabrina Giglio, Roberto Bonaiuti, Alessandro Mugelli, Maurizio Arico, Andrea Messeri, Alfredo Vannacci, Valentina Maggini

Summary: This observational study investigated the association between IL-6, IL-8, and TNF alpha genetic variants and response to opioid therapy in pediatric cancer patients. The study found that IL-6 and TNF alpha genetic variants could potentially serve as markers for baseline pain intensity and opioid dose requirements in these patients.

PHARMACEUTICS (2022)

Article Medicine, General & Internal

Non-Invasive Detection of a De Novo Frameshift Variant of STAG2 in a Female Fetus: Escape Genes Influence the Manifestation of X-Linked Diseases in Females

Aldesia Provenzano, Andrea La Barbera, Francesco Lai, Andrea Perra, Antonio Farina, Ettore Cariati, Orsetta Zuffardi, Sabrina Giglio

Summary: This study reports on a female fetus with diaphragmatic hernia and other malformations, and identifies a de novo frameshift variant of the X-linked STAG2 gene. The study shows that loss-of-function STAG2 variants lead to holoprosencephaly or Mullegama-Klein-Martinez syndrome, affecting only females, while missense mutations are associated with milder forms of the syndrome and follow X-linked recessive inheritance. In addition, the study suggests that STAG2 escapes X-inactivation and disease onset in females may be dependent on inadequate dosage of some transcripts.

JOURNAL OF CLINICAL MEDICINE (2022)

Article Medicine, General & Internal

Novel Germline PHD2 Variant in a Metastatic Pheochromocytoma and Chronic Myeloid Leukemia, but in the Absence of Polycythemia

Aldesia Provenzano, Massimiliano Chetta, Giuseppina De Filpo, Giulia Cantini, Andrea La Barbera, Gabriella Nesi, Raffaella Santi, Serena Martinelli, Elena Rapizzi, Michaela Luconi, Mario Maggi, Massimo Mannelli, Tonino Ercolino, Letizia Canu

Summary: This study describes a new PHD2 (EGLN1) gene variant in a patient with metastatic Pheo and chronic myeloid leukemia (CML). The findings highlight the necessity of genetic analysis in all Pheo/PGL cases and suggest testing for PHD2 (EGLN1) gene variants in patients with metastatic disease and no evidence of polycythemia. A possible correlation between PHD2 (EGLN1) pathogenic variants and CML clinical course is also proposed.

MEDICINA-LITHUANIA (2022)

暂无数据